Verici Dx Plc (VRCI) ORD GBP0.001
Verici Dx plc is an immuno-diagnostics development company. The Company is focused on the kidney transplantation market. Its principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use next-generation sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplant. The Company's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The 23-gene signature identified in the Clarava test reflects the potential a graft recipient's immune system has to have an inflammatory response to the donated kidney.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.